The CEO Behind Kimberly-Clark's $40 Billion Gamble on Tylenol Maker

Core Insights - The article discusses Mike Hsu's strategy to drive growth for the consumer company by expanding into Kenvue's higher-margin health products, which are considered risky [1] Company Strategy - Mike Hsu is focusing on leveraging Kenvue's health products to enhance profit margins despite the associated risks [1] Market Implications - The shift towards higher-margin health products indicates a potential change in market dynamics, as the company aims to capture more value in a competitive landscape [1]